U.K. authorizes Novavax’s COVID-19 shot

0
85

Shares of Novavax Inc. NVAX, -6.03% gained 0.9% in premarket trading on Thursday after the company said its COVID-19 vaccine received conditional authorization in the U.K. The protein-based vaccine, which is called Nuvaxovid, requires two shots spaced 21 days apart and can be used in adults. The U.K. has already ordered up to 60 million doses of Novavax’s vaccine. The company announced that it filed for authorization in the U.S. on Monday. Novavax’s stock has tumbled 68.5% over the past year, while the S&P 500 SPX, +0.94% has gained 19.9%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Real-estate agents’ commission rates are shrinking amid a seller’s market — but that doesn’t mean they’re losing money
Next articleU.S. initial jobless claims fell at end of January

LEAVE A REPLY

Please enter your comment!
Please enter your name here